Pharmacological Inhibition of Diabetic Retinopathy: Aminoguanidine and Aspirin

Diabetes

Volumn 50, Issue 7, 2001, Pages 1636-1642

  Kern, Timothy S ^a   Engerman, Ronald L ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ALBUMINOID; AMINOGUANIDINE; ARGININE; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; GUANIDINE DERIVATIVE; LYSINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOSIDINE;

ANIMAL; ARTICLE; DIABETIC RETINOPATHY; DOG; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLUCOSURIA; KIDNEY; METABOLISM; NERVE CONDUCTION; RANDOMIZATION; RETINA BLOOD VESSEL; THROMBOCYTE AGGREGATION; ULNAR NERVE;

ALBUMINS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARGININE; ASPIRIN; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DOGS; GLYCOSURIA; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; HEMOGLOBIN A, GLYCOSYLATED; KIDNEY; LYSINE; NEURAL CONDUCTION; PLATELET AGGREGATION; RANDOM ALLOCATION; RETINAL VESSELS; ULNAR NERVE;

EID: 0035409354     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.50.7.1636     Document Type: Article

References (61)

1. Engerman RL, Bloodworth JMB Jr, Nelson S: Relationship of microvascular disease in diabetes to metabolic control. Diabetes 26:760-769, 1977
2. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
3. Engerman RL, Kern TS: Experimental galactosemia produces diabetic-like retinopathy. Diabetes 33:97-100, 1984
4. Robison WG Jr, Nagata M, Laver N, Hohman TC, Kinoshita JH: Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor. Invest Ophthalmol Vis Sci 30:2285-2292, 1989
5. Takahashi Y, Augustin W, Wyman M, Kador PF: Quantitative analysis of retinal vessel changes in galactose-fed dogs. J Ocular Pharmacol 9:257-269, 1993
6. Engerman RL, Kern TS: Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs. Diabetes 42:820-825, 1993
7. Kern TS, Engerman RL: Comparison of retinal lesions in alloxan-diabetic rats and galactose-fed rats. Curr Eye Res 13:863-867, 1994
8. Kern TS, Engerman RL: A mouse model of diabetic retinopathy. Arch Ophthalmol 114:986-990, 1996
9. DAMAD Study Group: Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy: a multicenter randomized controlled clinical trial. Diabetes 38:491-498, 1989
10. Early Treatment of Diabetic Retinopathy Research Group: Effects of aspirin treatment on diabetic retinopathy. Ophthalmol 98:757-765, 1991
11. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232:1629-1632, 1986
12. Kochakian M, Manjula BN, Egan JJ: Chronic dosing with aminoguanidine and novel advanced glycosylation end product-formation inhibitors ameliorates cross-linking of tail tendon collagen in STZ-induced diabetic rats. Diabetes 45:1694-1700, 1996
13. Odetti PR, Borgoglio A, DePascale A, Rolandi R, Adezati L: Prevention of diabetes-increased aging effect on rat collagen-linked fluorescence by aminoguanidine and rutin. Diabetes 39:796-801, 1990
14. Cameron NE, Cotter MA, Dines K, Love A: Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 35:946-950, 1992
15. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, Sweetland MA, Lancaster JR Jr, Williamson JR, McDaniel ML: Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41:552-556, 1992
16. Ellis EN, Good BH: Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism 40:1016-1019, 1991
17. Kihara M, Schmelzer JD, Poduslo JF, Curran GL, Nickander KK, Low PA: Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci U S A 88:6107-6111, 1991
18. Li YM, Steffes M, Donnelly T, Liu C, Full H, Basgen J, Bucala R, Vlassara H: Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci U S A 93:3902-3907, 1996
19. Soulis T, Sastra H, Thallas V, Mortensen SB, Wilkin M, Clausen JT, Bjerrum OJ, Petersen H, Lau J, Jerums G, Boel E, Cooper ME: A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes. Diabetologia 42:472-479, 1999
20. Soulis T, Cooper ME, Vranes D, Bucala R, Jerums G: Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int 50:627-634, 1996
21. Hammes H-P, Martin S, Federlin K, Geisen K, Brownlee M: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A 88:11555-11558, 1991
22. Hammes H-P, Syed S, Uhlmann M, Weiss A, Federlin K, Geisub K, Brownlee M: Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats. Diabetologia 38:269-273, 1995
23. Kern TS, Tang J, Mizutani M, Kowluru RA, Nagaraj RH, Romeo G, Podesta F, Lorenzi M: Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Invest Ophthalmol Vis Sci 41:3972-3978, 2000
24. Engerman RL, Finkelstein D, Aguirre G, Diddie K, Fox R, Frank R, Varma S: Appropriate animal models for research on human diabetes mellitus and its complications: ocular complications. Diabetes 31 (Suppl. 1):82-88, 1982
25. Engerman RL, Kern TS: Retinopathy in animal models of diabetes. Diabetes Metab Rev 11:109-120, 1995
26. Trinder P: Rapid determination of salicylate in biological fluids. Biochem J 57:301-305, 1954
27. Engerman RL, Kern TS: Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 36:808-812, 1987
28. Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, Cerami A, Bucala R: Hemoglogin-AGE: a circulating marker of advanced glycosylation. Science 258:651-653, 1992
29. Monnier VM, Sell DR, Abdul-Karim FW, Emancipator SN: Collagen browning and cross-linking are increased in chronic experimental hyperglycemia: relevance to diabetes and aging. Diabetes 37:867-872, 1988
30. Niwa T, Katsuzaki T, Miyazaki S, Miyazaki T, Ishizaki Y, Hayase F, Tatemichi N, Takei Y: Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 99:1272-1280, 1997
31. Kern TS, Engerman RL: Platelet aggregation in experimental diabetes and experimental galactosemia. Diabetes 33:846-850, 1984
32. Naveh-Floman N, Weissman C, Belkin M: Arachidonic acid metabolism by retinas of rats with streptozotocin-induced diabetes. Curr Eye Res 3:1135-1139, 1984
33. Engerman RL, Kern TS, Larson ME: Nerve conduction velocity in dogs is reduced by diabetes and not by galactosemia. Metabolism 39:638-640, 1990
34. Engerman RL, Kern TS, Larson ME: Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosemia in dogs. Diabetologia 37:141-144, 1994
35. Bilous RW, Mauer SM, Sutherland DER, Steffes MW: Mean glomerular volume and rate of development of diabetic nephropathy. Diabetes 38: 1142-1147, 1989
36. Kern TS, Engerman RL: Urinary protein excretion rates in experimentally diabetic dogs and experimentally galactosaemic dogs. Diabetologia 31: 928-932, 1988
37. Arauz-Pacheco C, Ramirez LC, Pruneda L, Sanborn GE, Rosenstock J, Raskin P: The effect of the aldose reductase inhibitor, ponalrestat, on the progression of diabetic retinopathy. J Diabetes Complications 6:131-137, 1992
38. Sorbinil Retinopathy Trial Research Group: A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 108:1234-1244, 1990
39. Bresnick G, Engerman R, Davis MD, de Venecia G, Myers FL: Patterns of ischemia in diabetic retinopathy. Trans Am Acad Ophthalmol Otolaryngol 81:694-709, 1976
40. Tilton RG, Chang K, Hasan KS, Smith SR, Petrash JM, Misko TP, Moore WM, Currie MG, Corbett JA, McDaniel ML, Williamson JR: Prevention of diabetic vascular dysfunction by guanidines: inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 42:221-232, 1993
41. Soulis-Liparota T, Cooper M, Dunlop M. Jerums G: The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 38:387-394, 1995
42. Yu PH, Zuo DM: Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications. Diabetologia 40:1243-1250, 1997
43. do Carmo A, Lopes C, Santos M, Proenca R, Cunha-Vaz J, Carvalho AP: Nitric oxide synthase activity and L-arginine metabolism in the retinas from streptozotocin-induced diabetic rats. Gen Pharmacol 30:319-324, 1998
44. Giardino I, Fard AK, Hatchell DL, Brownlee M: Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 47:1114-1120, 1998
45. Kowluru RA, Engerman RL, Kern TS: Effects of aminoguanidine on hyperglycemia-induced retinal metabolic abnormalities (Abstract). Diabetes 48 (Suppl. 1):A19, 1999
46. Kern TS, Tang J, Mizutani M, Kowluru RA, Nagaraj RH, Romeo G, Podesta F, Lorenzi M: Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Invest Ophthalmol Vis Sci 41:3972-3978, 2000
47. Kern TS, Engerman RL: Arrest of glomerulopathy in diabetic dogs by improved glycemic control. Diabetologia 33:522-525, 1990
48. Engerman RL, Kern TS: Hyperglycemia and development of glomerular pathology: diabetes compared with galactosemia. Kidney Int 36:41-45, 1989
49. Engerman RL, Kern TS: Dissociation of retinopathy and nephropathy in animal models of diabetes: diabetes vs. galactosemia. In Hyperglycemia, Diabetes and Vascular Disease. Ruderman N, Williamson J, Brownlee M, Eds. New York, Oxford University Press, 1992, p. 151-161
50. Powell ED, Field RA: Diabetic retinopathy and rheumatoid arthritis. Lancet 2:17-18, 1964
51. Carroll WW, Geeraets WJ: Diabetic retinopathy and salicylates. Ann Ophthalmol 4:1019-1046, 1972
52. Engerman RL, Kern TS: Retinopathy in galactosemic dogs continues to progress after cessation of galactosemia. Arch Ophthalmol 113:355-358, 1995
53. Feke GT, Yoshida A, Ogasawara H, Konno S, Goger DG, Buzney SM, McMeel JW: Retinal blood flow increases following short-term aspirin usage in type I diabetics with no or minimal retinopathy. Ophthalmic Res 28:108-116, 1996
54. Pournaras C, Tsacopoulos M: [The metabolic regulation of the retinal blood flow and the role of prostaglandins (author's transl)]. Klin Monatsbl Augenheilkd 172:445-448, 1978
55. Yue DK, McLennan S, Handelsman DJ, Delbridge L, Reeve T, Turtle JR: The effect of salicylates on nonenzymatic glycosylation and thermal stability of collagen in diabetic rats. Diabetes 33:745-751, 1984
56. Brownlee M: Nonenzymatic glycosylation of macromolecules: prospects of pharmacologic modulation. Diabetes 41 (Suppl. 2):57-60, 1992
57. Edelstein D, Brownlee M: Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 41:26-29, 1992
58. Sajithlal GB, Chithra P, Chandrakasan G: Advanced glycation end products induce crosslinking of collagen in vitro. Biochim Biophys Acta 1407:215-224, 1998
59. Althaus JS, Andrus PK, Williams CM, VonVoigtlander PF, Cazers AR, Hall ED: The use of salicylate hydroxylation to detect hydroxyl radical generation in ischemic and traumatic brain injury: reversal by tirilazad mesylate (U-74006F). Mol Chem Neuropathol 20:147-162, 1993
60. Dinis TC, Maderia VM, Almeida LM: Action of phenolic derivatives (acetaminophen, salicylate, and 5-aminosalicylate) as inhibitors of membrane lipid peroxidation and as peroxyl radical scavengers. Arch Biochem Biophys 315:161-169, 1994
61. Boeri D, Maiello M, Lorenzi M: Increased prevalence of microthrombosis in retinal capillaries of diabetic individuals. Diabetes 50:1432-1439, 2001